[Value of adjuvant treatment applying the "CYVDIC" program after surgical treatment of soft tissue sarcomas. Preliminary communication].
The EORTC Soft Tissue and Bone Sarcoma Cooperative Group carries out since 1978, prospective study of the "CYVADIC" (Cyclophosphamide, Doxorubicin , Vincristine and Dacarbazine) programme applied in the postoperative course in patients with soft tissue sarcomas. The group of 24 patients treated in the Oncology Center-Institute in Warsaw entering this international programme is presented. Results so far obtained by the EORTC Cooperative Group concerning 358 patients introduced from over 15 oncologic centers from various European countries are discussed. Neither the improved survival nor extension of the free of metastases period in patients treated with chemotherapy have been observed in comparison with the control groups. The authors conclude that at present time there is not any evidence indicating the favourable results of treatment applying the "Cyvadic" programme as adjuvant therapy in the postoperative course of treatment of soft tissue sarcomas.
Ruka
W
W
Siedlecki
P
P
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012509:Sarcoma / Q000601:surgery / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000601:surgery / Q000628:therapy*; D014750:Vincristine
D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide
Wartość leczenia uzupełniajacego programem--"cyvadic" po operacji miesaków tkanek miekkich doniesienie wstepne.